Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000031307 | SCV000300399 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000031307 | SCV000326505 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000637352 | SCV000758807 | pathogenic | Hereditary breast ovarian cancer syndrome | 2019-10-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant has not been reported in the literature in individuals with BRCA2-related disease. ClinVar contains an entry for this variant (Variation ID: 37726). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Glu386Lysfs*13) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. |
Sharing Clinical Reports Project |
RCV000031307 | SCV000053912 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2008-01-22 | no assertion criteria provided | clinical testing | |
Laboratory for Genotyping Development, |
RCV003162266 | SCV002758410 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |